ClinicalTrials.gg

Program

aletekitug

Also written as “GSK1070806”, “Aletekitug” and “Aletekitug (GSK1070806)”.

Its studies are mostly in Dermatitis, Atopic · Colitis, Ulcerative · Delayed Graft Function · Inflammatory Bowel Diseases · Diabetes Mellitus, led by GlaxoSmithKline.

Furthest: phase 2, since Jul 12, 20129 company-led studies, 2 open or runningNext primary completion: Mar 5, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline92 open or runningphase 2since Jul 12, 2012Dec 17, 2009Mar 5, 2028phase 1 · NCT07747480

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2009First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT01035645 · 78 enrolled · United Kingdom
  2. Jul 12, 2012Phase 2 study in Diabetes MellitusNCT01648153 · 37 enrolled · Spain, United Kingdom
  3. Mar 14, 2016Phase 2 study in Delayed Graft FunctionNCT02723786 · 7 enrolled · Spain, United Kingdom
  4. Jul 14, 2021Phase 1 study in Dermatitis, AtopicNCT04975438 · 34 enrolled · United States, Canada
  5. Oct 18, 2022Phase 1 study in Dermatitis, AtopicNCT05590338 · 38 enrolled · United States
  6. Aug 11, 2023Phase 2 study in Dermatitis, AtopicNCT05999799 · 161 enrolled · United States, Argentina, Bulgaria and more
  7. Jun 3, 2024Phase 2 study in Dermatitis, AtopicNCT06447506 · 79 enrolled · United States, Argentina, Bulgaria and more
  8. Jul 31, 20262 phase 1 studies in Colitis, UlcerativeNCT07747480, NCT07747467
  9. Oct 28, 2026Primary completion moved from 2028-07-31 to 2029-03-21Date moved laterphase 1 · +8 months · NCT07747467

Ahead

  1. Mar 5, 2028Primary completion: phase 1 study in Colitis, UlcerativeNCT07747480
  2. Mar 21, 2029Primary completion: phase 1 study in Colitis, UlcerativeNCT07747467

TargetBeta

IL18 →read by rule
“Interleukin-18 inhibitor”ChEMBL 37, by rule

Other programs on IL18

ProgramCompanyFurthest phaseStudies
arumakimigNovartisphase 27
camoteskimabruleapollo-therapeutics-ltdphase 25
GHZ339Novartisphase 21
BLN-481rulebeeline-medicines-corporationphase 11
GSK4528287GlaxoSmithKlinephase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07747480Colitis, Ulcerative · United Kingdom1RecruitingMar 5, 202816
NCT07747467Colitis, Ulcerative · United Kingdom1RecruitingMar 21, 20298
NCT06447506Dermatitis, Atopic · United States, Argentina, Bulgaria and more2TerminatedJul 29, 202579
NCT05999799Dermatitis, Atopic · United States, Argentina, Bulgaria and more2TerminatedJul 23, 2025161
NCT05590338Dermatitis, Atopic · United States1CompletedJul 12, 202338
NCT04975438Dermatitis, Atopic · United States, Canada1CompletedDec 19, 202234
NCT02723786Delayed Graft Function · Spain, United Kingdom2TerminatedMar 31, 20177
NCT01648153Diabetes Mellitus · Spain, United Kingdom2CompletedSep 201337
NCT01035645Inflammatory Bowel Diseases · United Kingdom1CompletedJul 11, 201278

How it is read

Names in the registry

  • “GSK1070806”, 8 entries
  • “Aletekitug”, 1 entry
  • “Aletekitug (GSK1070806)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.